Winton Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Winton Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$164K	Buy	+59,300	New	+$239K	0.01%	979

Other funds holding ZNTL

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Pfizer New York $164M AUM 53.62% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Winton Group's ZNTL Position: Q3 2026 in Review

Winton Group opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q3 2026: 59,300 shares worth $164K. The stake represents 0.01% of the portfolio and ranks #979 among its holdings.

60 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.

Winton Group held 59,300 shares of Zentalis Pharmaceuticals worth $164K as of Q3 2026.
Zentalis Pharmaceuticals was a new Winton Group position in Q3 2026.
Zentalis Pharmaceuticals made up 0.01% of Winton Group's portfolio in Q3 2026, its #979 holding.
60 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.

Based on Winton Group's 13F filing for Q3 2026, filed 12 Nov 2026.